-
Discontinuation of Disease Modifying Drugs in Elderly Patients with Multiple Sclerosis: A Retrospective Cohort Study
Vol 1, 2023 - -
Frequency of latent tuberculosis in patients with multiple sclerosis screened for the prescription of alemtuzumab
Vol 1, 2023 - -
High-dose oral methylprednisolone treatment for AQP4 positive NMOSD attacks
Vol 1, 2023 - -
Importance of MOG-IgG in longitudinally extensive optic neuritis (LEON): a case report
Vol 1, 2023 -
Publications in other proceedings
-
BCTRIMS 2024
Discontinuation of Disease Modifying Drugs in Older Multiple Sclerosis Patients with Stable Disease: A Retrospective Observational Study
-
BCTRIMS 2024
Antibody Awareness and Diagnosis Recognition in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: A Cross-Sectional Study
-
BCTRIMS 2024
Profile of infusion-associated reactions with Alemtuzumab in a Brazilian reference center.
-
BCTRIMS 2024
Nonalcoholic steatohepatitis as an important differential diagnosis for drug-induced liver injury in patients using fingolimod – a case report.
-
BCTRIMS 2024
Unveiling the Silent Threat: Exploring Latent Tuberculosis in Multiple Sclerosis Patients Undergoing Novel Therapies
Streamline your Scholarly Event
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
